Wikidata

(Q61975901)

English

A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC

clinical trial

In more languages
default values for all languages
No label defined

No description defined

Statements

title
Phase II Trial of Exploring the Predictive Factors of Docetaxol Plus Capecitabine(TX) Regimen and Oxaliplatin Plus Capecitabine (XELOX) Regimen in the First Line Treatment of Patients With Metastatic Gastric Cancer (MGC) (English)
0 references
sponsor
Fudan University
0 references
start time
August 2012
0 references
end time
December 2013
0 references
number of participants
120
0 references
research intervention
capecitabine
0 references
oxaliplatin
0 references
docetaxel
0 references
minimum age
18 year
0 references
maximum age
75 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q61975901&oldid=2149404596"